Published in Br J Cancer on June 15, 2001
Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol (2011) 1.93
The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res (2011) 1.30
Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer (2003) 0.95
The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res (2010) 0.92
Epigenetic biomarkers of T-cells in human glioma. Epigenetics (2012) 0.92
Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep (2016) 0.91
Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Clin Exp Immunol (2009) 0.79
Extracellular 2'5'-oligoadenylate synthetase 2 mediates T-cell receptor CD3-ζ chain down-regulation via caspase-3 activation in oral cancer. Immunology (2015) 0.78
Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br J Cancer (2002) 0.77
Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer. Br J Cancer (2003) 0.76
Covert operations: cancer's many subversive tactics in overcoming host defenses. Trans Am Clin Climatol Assoc (2013) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol (1994) 3.35
Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med (1993) 2.17
Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest (1998) 1.80
Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res (1996) 1.46
Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer (1993) 1.36
Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res (1995) 1.33
Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer (1995) 1.25
Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest (1998) 1.22
Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res (1999) 1.17
Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation. J Exp Med (1999) 1.16
T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut (1997) 1.14
Role of the multiple T cell receptor (TCR)-zeta chain signaling motifs in selection of the T cell repertoire. J Exp Med (1997) 1.09
Mechanisms responsible for signaling and functional defects. J Immunother (1998) 1.04
Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity. Clin Exp Immunol (1988) 1.03
Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer (1996) 0.96
Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J Immunol (1999) 0.91
In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother Emphasis Tumor Immunol (1995) 0.82
Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. Br J Cancer (1999) 0.80
Serial immune function testing to predict clinical disease relapse in patients with solid tumors. Cancer Immunol Immunother (1983) 0.80
Proliferation of hematopoietic cell lines induced by a soluble factor derived from human squamous cell carcinomas of the head and neck. Cancer Immunol Immunother (1994) 0.80
Immunologic approaches to the management of ovarian carcinoma. Semin Oncol (1984) 0.78
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 2.17
Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res (1989) 1.84
Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol (1986) 1.74
Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer (2005) 1.69
Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology (1990) 1.63
TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene (2009) 1.52
A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods (2007) 1.49
Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol (1999) 1.48
Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res (1996) 1.46
Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res (1990) 1.45
Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer (1992) 1.45
Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res (1999) 1.44
Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods (1992) 1.44
Gene amplification and gene dosage in cell lines derived from squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer (1991) 1.42
Mesosomes: membranous bacterial organelles. Bacteriol Rev (1975) 1.35
A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products. Cytotherapy (2008) 1.35
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer (2013) 1.34
Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res (2001) 1.32
Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther (1996) 1.31
Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res (2000) 1.30
Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. Oral Oncol (1997) 1.29
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med (2001) 1.26
Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes Cancer (1990) 1.24
Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods (1992) 1.22
Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest (1998) 1.22
Activation of Raf by ionizing radiation. Nature (1996) 1.22
The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer (2001) 1.22
Abnormalities of T lymphocyte subsets in patients with progressive systemic sclerosis (PSS, scleroderma). J Lab Clin Med (1981) 1.21
Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol (2005) 1.21
Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J Natl Cancer Inst (1991) 1.20
Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. Br J Cancer (2000) 1.20
Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol (2000) 1.20
Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol (1987) 1.19
Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system? Br J Cancer (2005) 1.17
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res (1996) 1.17
Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res (1999) 1.17
Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res (2000) 1.16
Use of antibody to membrane adenosine triphosphatase in the study of bacterial relatioships. J Bacteriol (1971) 1.13
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ (2009) 1.13
Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood (1998) 1.13
Lymphocyte subpopulations at the site of "piecemeal" necrosis in end stage chronic liver diseases and rejecting liver allografts in cyclosporine-treated patients. Lab Invest (1984) 1.12
IgA-containing circulating immune complexes in patients with igA nephropathy. Am J Med (1983) 1.12
Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology (1985) 1.12
Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol (1997) 1.10
A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res (1988) 1.10
T-lymphocyte subsets in liver tissues of patients with primary biliary cirrhosis (PBC), patients with primary sclerosing cholangitis (PSC), and normal controls. J Clin Immunol (1984) 1.10
Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate (2000) 1.09
Isolation, phenotyping, and functional analysis of lymphocytes from human liver. Clin Immunol Immunopathol (1990) 1.09
The presence of IgE on the surface of lymphocytes in nasal polyps. J Allergy Clin Immunol (1975) 1.09
Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells. Cell Immunol (1991) 1.09
Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol (2014) 1.08
T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol (1993) 1.07
Cytokines, immunoglobulins, and bacterial pathogens in middle ear effusions. Arch Otolaryngol Head Neck Surg (1995) 1.07
Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res (1999) 1.05
Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods (1986) 1.05
Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem (1997) 1.04
The in vivo effect of hepatotrophic factors augmenter of liver regeneration, hepatocyte growth factor, and insulin-like growth factor-II on liver natural killer cell functions. Hepatology (1997) 1.04
Mechanisms responsible for signaling and functional defects. J Immunother (1998) 1.04
Immune system differences in men with hypo- or hypercholesterolemia. Clin Immunol Immunopathol (1997) 1.03
Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res (1999) 1.03
Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood (2000) 1.02
Tissue distribution of human NK cells studied with anti-Leu-7 monoclonal antibody. J Immunol (1983) 1.02
Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer (1989) 1.02
Immunodiagnosis of mesothelioma: use of antimesothelial cell serum in an indirect immunofluorescence assay. Cancer (1979) 1.02
Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic. Cell Immunol (1993) 1.01
Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res (1996) 1.01
Natural killer activity of human liver-derived lymphocytes in various liver diseases. Hepatology (1991) 1.01
Analysis of intestinal lymphocyte subpopulations in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Am J Clin Pathol (1987) 1.00
Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry (2000) 1.00
Candida albicans chorioamnionitis associated with preterm labor and sudden intrauterine demise of one twin. A case report. J Reprod Med (2000) 0.99
K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res (1997) 0.99
Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res (1998) 0.99
Soluble mediators from mononuclear cells increase the synthesis of glycosaminoglycan by dermal fibroblast cultures derived from normal subjects and progressive systemic sclerosis patients. Arthritis Rheum (1985) 0.98
Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci (1996) 0.98
In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg (1988) 0.98
Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol (2000) 0.97
Nonsecretory apoptotic killing by human NK cells. J Immunol (1996) 0.97
Clinical and serologic study of Sjögren's syndrome in patients with progressive systemic sclerosis. Arthritis Rheum (1983) 0.97
Expression and function of CD7 molecule on human natural killer cells. J Immunol (1994) 0.96
Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer (1996) 0.96
Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer (1986) 0.96
Antibody to adenosine triphosphatase from membranes of Micrococcus lysodeikticus. Biochemistry (1970) 0.96
Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int J Cancer (1994) 0.95
Phenotypic and functional characteristics of lymphocytes isolated from liver biopsy specimens from patients with active liver disease. Hepatology (1992) 0.95
Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol (1992) 0.95
Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer (2003) 0.95
A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res (2000) 0.94
Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother (1986) 0.94
Changes of liver-resident NK cells during liver regeneration in rats. J Immunol (1995) 0.94
Surface immunoglobulin on activated human peripheral blood thymus-derived cells. J Clin Invest (1976) 0.94
Signaling via CD7 molecules on human NK cells. Induction of tyrosine phosphorylation and beta 1 integrin-mediated adhesion to fibronectin. J Immunol (1994) 0.93
Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res (1993) 0.93
Adhesion characteristics of human interleukin 2-activated natural killer cells. Cell Immunol (1991) 0.93
Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation (1997) 0.92
In vitro cytokine production by normal human peripheral blood mononuclear cells as a measure of immunocompetence or the state of activation. Clin Diagn Lab Immunol (1994) 0.92
Immunologic characterization of chronic lymphocytic leukemia cells. Cancer (1977) 0.92
Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. Arthritis Rheum (1983) 0.92
Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res (1992) 0.92